Research progress of metformin in tumor immunotherapy
10.3760/cma.j.cn371439-20220228-00054
- VernacularTitle:二甲双胍在肿瘤免疫治疗中的研究进展
- Author:
Tingting NING
1
;
Qinyong HU
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Metformin;
Neoplasms;
Immune check inhibitors;
PD-1;
PD-L1
- From:
Journal of International Oncology
2022;49(5):292-295
- CountryChina
- Language:Chinese
-
Abstract:
In recent decades, immune checkpoint inhibitors (ICIs) have ushered in a new era in oncology treatment. Despite the remarkable efficacy of ICIs, there are still many patients who do not benefit from immunotherapy alone. Combination therapy is currently the main research direction in China and abroad. Metformin can enhance the number and function of T cells, affect macrophage polarization, promote natural killer cell activation and regulate immune checkpoint expression. A large number of preclinical and clinical studies are exploring the efficacy and safety of ICIs in combination with metformin in different tumors.
